Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole

J Transl Med. 2021 Feb 3;19(1):50. doi: 10.1186/s12967-021-02721-9.

Authors

L D Crosby¹, S Kalanidhi¹, A Bonilla^{1

2}, A Subramanian¹, J S Ballon¹, H Bonilla³

Affiliations

¹ Stanford University School of Medicine, Stanford, USA.
² University of Michigan, College of Literature, Sciences, and Arts, Ann Arbor, MI, USA.
³ Stanford University School of Medicine, Stanford, USA. hbonilla@stanford.edu.

No abstract available

Publication types

Letter

MeSH terms

Aripiprazole / therapeutic use
Fatigue
Fatigue Syndrome, Chronic* / drug therapy
Humans
Off-Label Use
Retrospective Studies

Substances

Aripiprazole

Grants and funding

R25 AI147369/AI/NIAID NIH HHS/United States